PRISM BioLab

PRISM BioLab is a biotechnology company focused on discovering small molecule inhibitors of protein-protein interaction (PPI) targets. They utilize their proprietary PepMetics technology to create orally available drugs for various diseases, including cancer and autoimmune disorders. This technology addresses the challenge of targeting PPIs, previously considered 'undruggable', by mimicking crucial peptide structures.

Buy Funded Startups lists

Funding Round:

Funding Amount: $10.3M

Date: 24-Jan-2024

Investors: Eli Lilly and Company, Santec Holdings Corporation

Markets: Biotechnology, Pharmaceuticals, Drug Discovery

HQ: Tokyo, Tokyo, Japan

Founded: 2006

Website: https://www.prismbiolab.com/

LinkedIn: https://www.linkedin.com/company/prismbiolab-co-ltd

Twitter:

Instagram: